fda approves first oral glp-1 obesity drug august 14 2025 A new option is now part of medicine. approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, for adults with obesity or overweight with at least one weight-related Weight-loss GLP-1 pill approved for

Co-toxicity of Endotoxin and Indoxyl Sulfate, Gut-Derived Bacterial Metabolites, to Vascular Endothelial Cells in Coronary Arterial Disease Accompanied by Gut Dysbiosis

Lancet 390 , 27692778 (2017)

Reconstitution Steps Draw 3.0 mL bacteriostatic water using a sterile syringe

Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial

In addition to GLP-1RAs, pioglitazone and SGLT-2 inhibitors are two other classes of diabetic medications that have shown promise in reducing the risk of cardiovascular disease, albeit through different mechanisms

A study demonstrated that broccoli could increase glutathione synthesis in the liver, resulting in increased antioxidant activities in the liver